Obalon

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Obalon and buy or sell other stocks, ETFs, and their options commission-free!

About OBLN

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. 

CEO
Venkateswarlu Nelabhotla, MBA
CEOVenkateswarlu Nelabhotla, MBA
Employees
18
Employees18
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
Founded
Employees
18
Employees18

OBLN Key Statistics

Market cap
110.05M
Market cap110.05M
Price-Earnings ratio
-0.18
Price-Earnings ratio-0.18
Dividend yield
Dividend yield
Average volume
54.77K
Average volume54.77K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$33.16
52 Week high$33.16
52 Week low
$1.75
52 Week low$1.75

Stock Snapshot

With a market cap of 110.05M, Obalon(OBLN) trades at $15.68. The stock has a price-to-earnings ratio of -0.18.

On 2026-05-22, Obalon(OBLN) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Obalon(OBLN) stock has reached 0, versus its average volume of 54.77K.

The stock's 52-week range extends from a low of $1.75 to a high of $33.16.

The stock's 52-week range extends from a low of $1.75 to a high of $33.16.

People also own

Based on the portfolios of people who own OBLN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.